Advancing Access to Precision Medicine Act

Advocacy on health care issues related to genetics and genetic testing, including H.R. 3235 - Access to Genetic Counselor Services Act of 2019; H.R.4393 - Advancing Access to Precision Medicine Act; and S. 3404/HR 6102 - Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Congressional Personalized Medicine Caucus Barriers to Genetic Testing for ALS/Congressional ALS Caucus Briefing H.R. 4393 Advancing Access to Precision Medicine Act H.R. 4144 Ending the Diagnostic Odyssey Act Draft bill Personalizing Medications Act Draft bill Rare Cancer Awareness, Research, and Treatment Act Medicare Coverage of Innovative Technology (MCIT)Pathway CMS Coverage for Minimal Residual Disease Testing CMS National Coverage Analysis for Colorectal Cancer Screening using Blood-Based Biomarker Testing CMS Laboratory Date-of-Service Policy Changes in CY 2021 Hospital OPPS Proposed Rule Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

Client expense: $27,595 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office

Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.4393 - Advancing Access to Precision Medicine Act H.R.3235 - Access to Genetic Counselor Services Act of 2019 S. 2741/H.R. 4932 CONNECT for Health Act Scope of practice for non-physician providers Coding practices for molecular diagnostics

Client expense: Not reported · Firm income: $65,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR4393, Advancing Access to Precision Medicine Act H.R. 6201, Families First Coronavirus Response Act H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act H.R. 6800, The Health and Economic Recovery Omnibus Emergency Solutions Act


Client expense: Not reported · Firm income: $37,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement and policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 preparedness products and services PASTEUR Act (S.4760)

Client expense: $230,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

Advocated for passage of the ALS Disability Insurance Act (HR 1407, S 578) which would eliminate the five month waiting period for individuals with ALS to obtain Social Security disability insurance. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing.

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for robust funding of the national newborn screening program. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated on the Promising Pathway Act (S.3872) and the ACT for ALS Act (H.R.7071). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. H.R. 6800, HEROES Act and related COVID-19 packages, support various provisions relevant to people with NMDs including increased federal support for state Medicaid programs; Medicaid maintenance of effort provisions; nationwide reopening of Marketplace special enrollment period; expansion of paid sick leave and paid family and medical leave; making permanent flexibilities to allow Medicare beneficiaries to continue accessing healthcare through telehealth; more resources to enhance testing and contact tracing in underserved communities; opposing waivers from IDEA and the Rehab Act; and better data collection on the impact of COVID-19 on people with disabilities. Continuing to support passage of legislation and proposals to protect patients from surprise medical billing and hold patients harmless.

H.R.4393 - Advancing Access to Precision Medicine Act H.R.3235 - Access to Genetic Counselor Services Act of 2019 S. 2741/H.R. 4932 CONNECT for Health Act Scope of practice for non-physician providers

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR4393, Advancing Access to Precision Medicine Act H.R. 6201, Families First Coronavirus Response Act H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act H.R. 6800, The Health and Economic Recovery Omnibus Emergency Solutions Act


Client expense: Not reported · Firm income: $37,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement PASTEUR Act (S.4760)

Client expense: $370,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act)

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated on the Promising Pathway Act (S.3872) and the ACT for ALS Act (H.R.7071). Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency. H.R. 6800, HEROES Act and Senate-led COVID-19 package, support various provisions relevant to people with NMDs including increased federal support for state Medicaid programs; Medicaid maintenance of effort provisions; nationwide reopening of Marketplace special enrollment period; expansion of paid sick leave and paid family and medical leave; making permanent flexibilities to allow Medicare beneficiaries to continue accessing healthcare through telehealth; more resources to enhance testing and contact tracing in underserved communities; opposing waivers from IDEA and the Rehab Act; and better data collection on the impact of COVID-19 on people with disabilities. H.R. 6420/S. 3652 All Dependents Count Act, support passage. H.R. 3630, No Surprises Act; S. 1895, Lower Health Care Costs Act; S. 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; H.R. 5800, Ban Surprise Billing Act; H.R. 5826 Consumer Protections Against Surprise Medical Bills Act, support passage of legislation to protect patients from surprise medical billing that holds patients harmless H.R. 127, Compassionate Access, Research Expansion and Respect States (CARERS) Act, support passage

Advocated for passage of the ALS Disability Insurance Act (HR 1407, S 578) which would eliminate the five month waiting period for individuals with ALS to obtain Social Security disability insurance. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019.

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)

Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R.4393 - Advancing Access to Precision Medicine Act H.R.3235 - Access to Genetic Counselor Services Act of 2019 S. 2741/H.R. 4932 CONNECT for Health Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR4393, Advancing Access to Precision Medicine Act H.R. 6201, Families First Coronavirus Response Act H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act

Client expense: Not reported · Firm income: $37,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for funding for the FDA Orphan Products Grants Program. Advocated for passage of the Medical Nutrition Equity Act (H.R.2501). Advocated for Members to join the Rare Disease Caucus and the ALS Caucus. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated for the continuance of the Rare Pediatric Disease Priority Review Voucher Program within the context of the Creating Hope Reauthorization Act (H.R.4439) Advocated for passage of Families First Coronavirus Response Act (HR 6201) and Coronavirus Preparedness and Response Supplemental Appropriations Act (HR 6704). Advocated for a joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers" (H.J. Res. 74 / S.J. Res. 52).

Advocated for passage of the ALS Disability Insurance Act (HR 1407, S 578) which would eliminate the five month waiting period for individuals with ALS to obtain Social Security disability insurance. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for passage of Families First Coronavirus Response Act (HR 6201). Advocated for a joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers" (H.J. Res. 74 / S.J. Res. 52).

Client expense: $100,000 · Firm income: Not reported

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6102/S.3404 - The Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act. HR 6201- Families First Coronavirus Response Act; HR 748 - Coronavirus Aid, Relief, and Economic Security Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID preparedness products and services (H.R. 748)

Client expense: $310,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R.4393 - Advancing Access to Precision Medicine Act H.R.3235 - Access to Genetic Counselor Services Act of 2019

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR4393, Advancing Access to Precision Medicine Act H.R. 6201, Families First Coronavirus Response Act H.R. 748 Coronavirus Aid, Relief, and Economic Security Act (CARES) Act

Client expense: Not reported · Firm income: $37,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care. Advocated for passage of H.R. 4393, the Advancing Access to Precision Medicine Act, provide for a State option under the State Medicaid plan to provide DNA sequencing clinical services for certain children. Advocated for passage of H.R. 3235, the Access to Genetic Counselor Services Act of 2019, to provide for expanded coverage of services provided by genetic counselors. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Advocated for passage of H.R. 986, the Protecting Americans with Preexisting Conditions Act of 2019, which would require the Administration to rescind its Section 1332 State Relief and Empowerment Waivers Guidance, released on October 22, 2018 (1332 guidance). The guidance would allow states to let individuals use advanced premium tax credits to purchase non-compliant short-term, limited duration insurance plans-which could further draw younger, healthier people out of the risk pool for comprehensive insurance and drive up premiums for those who need comprehensive coverage, such as individuals with neuromuscular conditions. Also advocated for the passage of H.R. 1010, legislation to provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect. Issues related to surprise medical billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019. Advocated for maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated for the continuance of the Rare Pediatric Disease Priority Review Voucher Program within the context of the Creating Hope Reauthorization Act (H.R.4439)

Advocacy on health care issues related to genetics and genetic testing, including H.R. 4393, Advancing Access to Precision Medicine Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. HR 4393- Advancing Access to Precision Medicine Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. xxxx - Discussion drafts of the Verifying Accurate, Leading-edge IVCT Development Act; S.1895 - The Lower Health Care Costs Act; H.R.861 - End Surprise Billing Act of 2019. H.R. 4393- Advancing Access to Precision Medicine Act

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393)

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE

The Protect Access to Cellular Transplant Act (H.R. 2498), all provisions; The Protect Access to Cellular Transplant Act (S. 1286), all provisions; The Advancing Access to Precision Medicine Act (H.R. 4393), all provisions.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare coverage of next generation sequencing based tests for cancer H.R.4393 - Advancing Access to Precision Medicine Act H.R.3235 - Access to Genetic Counselor Services Act of 2019

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare coverage of next generation sequencing based tests for cancer HR4393, Advancing Access to Precision Medicine Act H.R.3584, Laboratory Access for Beneficiaries Act

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Advocacy on health care issues related to genetics and genetic testing, including H.R. 4393, Advancing Access to Precision Medicine Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393)

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Verifying Accurate Leading-edge IVCT Development (VALID) Act House Discussion Draft Patient Centered Outcomes Research Institute Reauthorization Congressional Personalized Medicine Caucus H.R.4393 "Advancing Access to Precision Medicine Act" H.R. 4144 "Ending the Diagnostic Odyssey Act of 2019" H.R.3235 "Access to Genetic Counselor Services Act of 2019" S.2543 "Prescription Drug Pricing Reduction Act of 2019" CMS Potential Revisions to Laboratory Date of Service Policy in CY 2020 Hospital Outpatient Prospective Payment System Rule FDA Center for Devices and Radiological Health List of Patient Preference-Sensitive Priorities FDA Activities on Pharmacogenomic Tests Support for full appointment of Acting FDA Commissioner Ned Sharpless

Client expense: $34,864 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Medicare coverage of next generation sequencing based tests for cancer H.R.4393 - Advancing Access to Precision Medicine Act

Client expense: Not reported · Firm income: $58,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare coverage of next generation sequencing based tests for cancer HR4393, Advancing Access to Precision Medicine Act

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE